Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in cutaneous lupus erythematosus – mechanistic phase IV pilot
2025-523133-26-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anifrolumab in cutaneous lupus erythematosus (CLE), sponsored by Medical University of Vienna. Planned start Feb 2026; status: authorised.
02
Drugs
anifrolumab
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2025-523133-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523133-26-00.